A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

PHASE2TerminatedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 16, 2019

Primary Completion Date

April 16, 2020

Study Completion Date

April 24, 2020

Conditions
Cystic Fibrosis
Interventions
DRUG

BI 1265162

Inhalation solution

DRUG

Placebo

Inhalation solution

Trial Locations (26)

1090

Brussels - UNIV UZ Brussel, Brussels

3000

UZ Leuven, Leuven

13353

Charité - Universitätsmedizin Berlin, Berlin

15224

Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh

23219

Virginia Commonwealth University Health Systems, Richmond

27517

The University of North Carolina at Chapel Hill, Chapel Hill

29425

Medical University of South Carolina, Charleston

29684

HOP Perharidy, Roscoff

30625

Medizinische Hochschule Hannover, Hanover

32827

Nemours Children's Hospital, Orlando

34295

HOP Arnaud de Villeneuve, Montpellier

35385

Universitätsklinikum Gießen und Marburg GmbH, Giessen

45239

Ruhrlandklinik, Westdeutsches Lungenzentrum am Universitätsklinikum Essen gGmbH, Essen

46202

Riley Hospital for Children at Indiana University Health, Indianapolis

69495

HOP Lyon Sud, Pierre-Bénite

72076

Universitätsklinikum Tübingen, Tübingen

75019

HOP Robert Debré, Paris

75390

University of Texas Southwestern Medical Center, Dallas

75679

HOP Cochin, Paris

98195

University of Washington, Seattle

V1Y 1S1

St. Paul's Hospital, Vancouver

H2X 3E4

Centre Hospitalier de l'Universite de Montreal (CHUM), Montreal

08035

Hospital Vall d'Hebron, Barcelona

413 45

Sahlgrenska US, Göteborg, Gothenburg

141 86

Stockholm CF-Center , B59, Huddinge Universitetssjukhus, Stockholm

SW3 6NP

Royal Brompton Hospital, London

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY